Emerging evidence demonstrates antiviral effects from the AA/COX-2/PGE₂ pathway, highlighting therapeutic potential for RNA viruses.
Emerging evidence suggests that the AA/COX-2/PGE₂ axis exerts significant, yet context-dependent antiviral effects during RNA virus infections. Critical gaps remain in understanding the tissue-specific effects of this pathway during RNA virus infections, including the contributions of COX-2-derived metabolites and their molecular mechanisms of action. In vivo studies and clinical trials are needed to evaluate the therapeutic potential of targeting the AA/COX-2/PGE₂ axis, with available safe COX-2-inhibiting drugs approved for human use that allow such approaches. Knowledge derived from these assays could yield impactful therapeutic applications that significantly improve clinical outcomes in RNA virus infections.
No takes yet. Share an insight, caveat, or question.
Navarro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Expert Review of Anti-infective Therapy